A Dose Response Phase 2 Clinical Study of VLA1553 in Healthy Children Aged 1 to 11 Years

Conditions: Chikungunya Virus Infection Interventions: Biological: VLA1553 full dose; Biological: VLA1553 half dose; Biological: Control Sponsors: Valneva Austria GmbH Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials